If you are asking why peptide ads keep getting banned, the answer is usually a combination of platform policy enforcement and how your ads are structured. Understanding the root causes helps you build campaigns that last. Most advertisers assume bans are random, but there are clear patterns explaining almost every peptide ad ban.
We have analyzed hundreds of banned peptide ads across Meta, Google, and other platforms. The patterns are consistent enough that we can predict which ads will get banned before they go through review. By understanding these patterns, you can build campaigns that avoid enforcement entirely.
The Core Reasons Peptide Ads Get Banned
Platforms classify peptides inconsistently. Meta treats them as restricted healthcare products, Google requires pharmaceutical certification, and both platforms use automated systems scanning for health-related language. An ad passing on one platform may be banned on another.
Health claims are the number one trigger. Any language suggesting a peptide can treat, cure, or prevent a condition results in a ban. This includes implied claims like supports healthy weight, promotes muscle recovery, or balances hormones.
Branded drug names attract scrutiny. Mentioning semaglutide, tirzepatide, BPC-157, or any specific peptide by name increases ban likelihood, especially if the ad also references associated conditions.
Unaffiliated business documentation. If your business is not verified through BAV or equivalent processes, your ads will be treated with suspicion. Platforms require proof you are a legitimate healthcare provider.
Landing page non-compliance. Many peptide ads get banned because the landing page makes claims the ad itself does not. Meta and Google both review your landing page and will ban the ad if the page violates policies.
The Regulatory Framework Behind the Bans
FDA 503A and 503B set the boundaries for compounding pharmacy advertising. If you promote compounded peptides, you must operate within these frameworks. Your ads cannot claim FDA approval for compounded drugs because they are prepared under FDA-regulated conditions, not individually approved.
DSHEA 1994 governs supplement advertising and prohibits disease treatment claims. If your peptides are marketed as supplements, DSHEA applies directly. Supplement advertisers face additional scrutiny because the line between structure-function and disease claims is often blurred.
The BAV appeal pathway gives you a formal process to challenge bans. BAV verification also acts as a preventive measure reducing the likelihood of future bans.
How We Prevent Bans
Pre-audit before publishing. We review every ad component against platform policies and FDA regulations before submission. This catches issues before automated systems do.
Build regulatory-compliant landing pages. Every landing page includes FDA 503A or 503B disclaimers, a clear privacy policy, terms of service, and educational content avoiding treatment claims.
Use BAV verification proactively. We verify every client's business documentation before running peptide ads. This prevents many ban triggers from activating.
Case Study: From Banned to Profitable
A peptide company had 5 ad accounts banned over 3 months. Each ban was for similar health claim violations. We conducted a full audit, rebuilt their creative strategy around educational content, implemented BAV verification across all accounts, and created a compliance checklist. After the changes, their ads ran continuously for 8 months without a single ban.
More reading
Peptide Advertising Regulations
Ready to run these ads? Book a call at calendly.com/custodio-2/30min